FDA Grants Market Clearance to Diagnostic Blood Test for Alzheimer Disease
The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer disease.
The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer disease.
Patients with diabetes using glucagon-like peptide-1 (GLP-1) drugs face double the risk of developing neovascular age-related macular degeneration, highlighting crucial ocular health concerns.
The FDA approves clesrovimab-cfor, a new RSV vaccine, offering infants effective protection against severe respiratory illness during their first RSV season.
Innovative pain management strategies emerge as experts advocate for personalized, multifaceted approaches to chronic pain, likening treatment to a tailored cupcake.
A new study reveals the combination therapy enhances safety and efficacy for high-risk BRAF-mutated stage II melanoma.
Pharmacists lead the charge in implementing advanced therapeutics, navigating complex challenges and shaping the future of health care innovation.
Vepdegestrant was the first PROTAC to be evaluated in a phase 3 clinical trial.
Ambulatory pharmacists innovate care delivery, enhancing patient access and outcomes through home visits and harm reduction clinics for complex health needs.
The FDA has approved a groundbreaking single-pill combination therapy for hypertension, enhancing cardiovascular health with triple-agent efficacy.
Integrating specialty pharmacists into neurology teams enhances patient care, medication management, and clinical outcomes for chronic conditions.
The findings highlight the need for improved prescribing practices and patient outcomes.